Safety and effectiveness of hormonal contraception for women who use opioids: A systematic review

Society of Family Planning clinical recommendations: Contraception and abortion care for persons who use substances

“…The Centers for Disease Control Medical Eligibility Criteria does not include addiction as its own category or discuss medications to treat addiction and hence currently make no recommendation [74] . A recent systematic review of safety and efficacy of contraception among people who use opioids could find no theoretical safety concerns with contraception [75] . There are no limitations to prescribing any contraceptive method for patients who use opioids or other substances (aside from nicotine and alcohol, excluded in this guideline.…”

Factors Affecting Contraception Access and Use in Patients With Opioid Use Disorder

“…60 When considering the high rate of intravenous drug use and viral hepatitis in women with opioid use disorder, practitioners who do not routinely prescribe contraceptives may have concerns or misconceptions about potential drug interactions between contraceptives and opioids or other medications. 61 It is important to note that there are no documented clinically significant drug interactions with concurrent opioid and hormonal contraceptive use, 62 and other drug interactions with hormonal contraceptives are relatively rare, and can be addressed through evaluation with the US Medical Eligibility Criteria for Contraceptive Use and/or the US Selected Practice Recommendations for Contraceptive Use. 63,64…”

Contraceptive Challenges in Women With Common Medical Conditions

“…9 Women can use opioids and contraception with little concern for interactions. 10 Evidence from clinical and pharmacokinetic studies does not support the existence of drug interactions between hormonal contraceptives and non-rifamycin antibiotics. 11 CURRENT CONTRACEPTIVE USE For young, nulliparous women and reproductive women between pregnancies or who have completed childbearing, LARC should be the first consideration, with associated US Food and Drug Administrationeapproved lifespan, including levonorgestrel (LNG) IUS Mirena 52 mg (5 years), Liletta 52 mg (6 years), Kyleena 19.5 mg (5 years), and Skyla 13.5 mg (3 years), the copper TCu380A intrauterine device (IUD) Paragard (10 years), and etonogestrel subdermal implant Nexplanon (3 years).…”